

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

PCT / SE 2004 / 0 0 1 4 2 1

REC'D 26 OCT 2004

WIPO

PCT

## Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande                      AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer    0302666-3  
Patent application number

(86) Ingivningsdatum                      2003-10-07  
Date of filing

Stockholm, 2004-10-08

För Patent- och registreringsverket  
For the Patent- and Registration Office

  
Görel Gustafsson

Avgift  
Fee

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

## NOVEL COMPOUNDS

### Field of the Invention

- 5 The present invention discloses novel [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy.

### Background of the Invention

10

Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases and inflammatory bowel disease (IBD), as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa  
15 proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These two groups are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

20

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (CXCL8) and neutrophil-activating peptide 2 (CXCL7).

25

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (CCL2, CCL7 and CCL8), RANTES (CCL5), eotaxin (CCL11) and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (CCL3 and CCL4).

There is also a third chemokine family based upon the structural motif Cys-X<sub>3</sub>-Cys

(C-X<sub>3</sub>-C). This C-X<sub>3</sub>-C family is distinguished from the C-X-C and C-C families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues. CX<sub>3</sub>CL1 (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system as well as of monocytes, T cells, NK cells and mast  
5 cells.


Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors. In particular, the actions of CX<sub>3</sub>CL1 are mediated by the CX<sub>3</sub>CR1 receptor.

10 WO 01/25242 discloses certain [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives that are useful as antagonists of receptors linked to the C-X-C and C-C chemokine families, particularly as antagonists of the CXCR2 receptor.

15 The present invention relates to a group of compounds that are structurally similar to, but nevertheless generically distinct from, the compounds disclosed in WO 01/25242. The compounds of the present invention display surprisingly useful properties as antagonists of the CX<sub>3</sub>CR1 receptor.

20 Disclosure of the invention

The present invention provides compounds of formula (I)



(I)

wherein:

$R^1$  and  $R^2$  independently represent H, C1 to 8 alkyl, C2 to 8 alkenyl, C2 to 8 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; the latter four groups being optionally further substituted by one or more groups selected independently from OH, C1 to 6 alkoxy,  $CH_2OR^4$ ,  $NR^5R^6$ ,  $CO_2R^7$  and  $CONR^8R^9$ ;

$R^3$  represents C1 to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or alkynyl chain optionally including a O,  $NR^{10}$  or S atom in the chain; said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by phenyl or a 5 or 6 membered heteroaromatic ring containing 1 to 3 heteroatoms selected independently from O, S and N; said phenyl or heteroaromatic ring being optionally further substituted by one or more groups selected independently from halogen, C1 to 4 alkyl, OH, C1 to 4 alkoxy, CN,  $CO_2R^{11}$ ,  $NR^{12}R^{13}$ ,  $CONR^{14}R^{15}$ ,  $SO_2R^{16}$ ,  $NR^{17}SO_2R^{18}$  and  $SO_2NR^{19}R^{20}$ ;

X represents O or S(O);

$R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}$  and  $R^{20}$  independently represent H or C1 to 6 alkyl;

and pharmaceutically acceptable salts thereof.

The compounds of formula (I) may exist in enantiomeric and/or tautomeric forms. It is to be understood that all enantiomers, diastereomers, racemates, tautomers and mixtures thereof are included within the scope of the invention.

Unless otherwise indicated, the term "C1 to 8 alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 8 carbon atoms. Examples of such groups

include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl and hexyl. The terms "C1 to 6 alkyl" and "C1 to 4 alkyl" are to be interpreted analogously.

Unless otherwise indicated, the term "C2 to 8 alkenyl" referred to herein denotes a straight or branched chain alkyl group having from 2 to 8 carbon atoms and containing one carbon-carbon double bond. The term "C2 to 6 alkenyl" is to be interpreted analogously.

Unless otherwise indicated, the term "C2 to 8 alkynyl" referred to herein denotes a straight or branched chain alkyl group having from 2 to 8 carbon atoms and containing one carbon-carbon triple bond. The term "C2 to 6 alkenyl" is to be interpreted analogously.

Unless otherwise indicated, the term "C3 to 7 saturated or partially unsaturated cycloalkyl" referred to herein denotes a 3 to 7 membered non-aromatic carbocyclic ring optionally incorporating one or more double bonds. Examples include cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl.

Unless otherwise indicated, the term "C1 to 6 alkoxy" referred to herein denotes an oxygen substituent bonded to a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy and s-butoxy. The term "C1 to 4 alkoxy" is to be interpreted analogously.

Unless otherwise indicated, the term "halogen" referred to herein denotes fluorine, chlorine, bromine and iodine.

Examples of a five or six membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N include furan, thiophene, pyrrole, oxazole, oxadiazole, isoxazole, imidazole, thiazole, triazole, thiadiazole, pyridine, pyrimidine and pyrazine.

In the definition of  $R^3$ , the expression "said alkyl, alkenyl or alkynyl chain optionally including a O,  $NR^{10}$  or S atom in the chain" embraces a straight or branched chain

arrangement of 1 to 6 carbon atoms in which, where chemically feasible, the carbon chain is interrupted by, or terminates in, an O, S or NR<sup>10</sup> atom. The definition thus includes, for example, methylene, ethylene, propylene, hexamethylene, ethylethylene, -CH<sub>2</sub>CH<sub>2</sub>O-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>O-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>S- and -CH<sub>2</sub>CH<sub>2</sub>NR<sup>10</sup>-.

5

In one embodiment, X represents O. In another embodiment, X represents S(O).

In one embodiment, R<sup>1</sup> and R<sup>2</sup> independently represent H, optionally substituted C1 to 8 alkyl or optionally substituted C3 to 7 cycloalkyl.

10

In another embodiment, R<sup>1</sup> represents H or CH<sub>3</sub>. In another embodiment, R<sup>1</sup> represents H.

In another embodiment R<sup>2</sup> represents optionally substituted C1 to 8 alkyl or optionally substituted C3 to 7 cycloalkyl. In another embodiment, R<sup>2</sup> represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH<sub>2</sub>OR<sup>4</sup>.

15

In one embodiment, R<sup>3</sup> represents optionally substituted C1 to 6 alkyl that optionally includes an O atom in the chain. In another embodiment, R<sup>3</sup> represents C1 to 6 alkyl optionally including an O atom in the chain and substituted by optionally substituted phenyl. In another embodiment, R<sup>3</sup> represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

20

In one embodiment, X represents O, R<sup>1</sup> represents H or CH<sub>3</sub>; R<sup>2</sup> represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH<sub>2</sub>OR<sup>4</sup>; and R<sup>3</sup> represents C1 to 6 alkyl substituted by optionally substituted phenyl.

25

In another embodiment, X represents O, R<sup>1</sup> represents H; R<sup>2</sup> represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH<sub>2</sub>OR<sup>4</sup>; and R<sup>3</sup> represents

C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen,  
C1 to 6 alkoxy or CN.

In one embodiment, X represents S(O), R<sup>1</sup> represents H or CH<sub>3</sub>; R<sup>2</sup> represents C1 to 8  
5 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH<sub>2</sub>OR<sup>4</sup>; and R<sup>3</sup>  
represents C1 to 6 alkyl substituted by optionally substituted phenyl.

In another embodiment, X represents S(O), R<sup>1</sup> represents H; R<sup>2</sup> represents C1 to 8 alkyl  
substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH<sub>2</sub>OR<sup>4</sup>; and R<sup>3</sup> represents  
10 C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen,  
C1 to 6 alkoxy or CN.

Particular compounds of formula (I) include:

5-(benzyloxy)-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-  
15 *d*]pyrimidin-2(3*H*)-one;

7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}-5-[(3-  
methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}-5-(2-phenylethoxy)[1,3]thiazolo[4,5-  
*d*]pyrimidin-2(3*H*)-one;

20 5-(benzyloxy)-7-[[1*R*]-1-(hydroxymethyl)butyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-  
2(3*H*)-one;

7-[[1*R*]-1-(hydroxymethyl)butyl]amino}-5-[[1*S*]-1-phenylethyl]oxy][1,3]thiazolo[4,5-  
*d*]pyrimidin-2(3*H*)-one;

25 *N*-(3-[[7-[[1*R*]-1-(hydroxymethyl)butyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-  
*d*]pyrimidin-5-yl)oxy]methyl}phenyl)-*N*-methylmethanesulfonamide;

*N*-(3-[[7-[[1*R*]-1-(hydroxymethyl)-2-methylpropyl]amino]-2-oxo-2,3-  
dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl}phenyl)methanesulfonamide;

5-(benzyloxy)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-  
2(3*H*)-one;

30 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-  
*d*]pyrimidin-2(3*H*)-one;

7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(3-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(2-chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5 5-[(3-chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-  
d]pyrimidin-2(3*H*)-one;

5-[(4-chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-  
10 *d*]pyrimidin-2(3*H*)-one;

7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

4-[(7-([1-(hydroxymethyl)cyclopentyl]amino)-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy)methyl]benzonitrile;

15 (R,S)-7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-(1-phenylethoxy)-thiazolo[4,5-  
d]pyrimidin-2(3H)-one;

7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[[*(1S)*-1-phenylethyl]oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[[2-(3-chlorophenyl)ethyl]-(*R<sub>S</sub>*,*S<sub>S</sub>*)-sulfinyl]-7-[[*(1R)*-1-(hydroxymethyl)-3-  
20 methylbutyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-{[2-(2-bromophenyl)ethyl]-(*R<sub>s</sub>,S<sub>s</sub>*)-sulfinyl}-7-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(2,3-difluorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1(R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;

25 5-[benzyl-(*R*<sub>S</sub>,*S*<sub>S</sub>)-sulfinyl]-7-[[[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;

5-[(2-chlorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;

5-[(4-chlorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[[(1R)-1-(hydroxymethyl)-3-  
30 methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one;

5-[benzyl-(*R<sub>S</sub>,S<sub>S</sub>*)-sulfinyl]-7-[[*(1R)*-1-(hydroxymethyl)-2-methylpropyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one;


1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.



and pharmaceutically acceptable salts thereof.

According to the invention, we further provide a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof which comprises:

(a) when X in formula (I) represents O, reaction of a compound of formula (II)



(II)

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in formula (I);

with a compound of formula (III)




(III)

wherein R<sup>3</sup> is as defined in formula (I) and is independent of the R<sup>3</sup> group in formula (II);

or

(b) when X in formula (I) represents S(O), oxidation of a compound of formula (IV)



(IV)

wherein  $R^1$ ,  $R^2$  and  $R^3$  are as defined in formula (I); with one equivalent of an oxidising agent;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of

5 formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

In process (a), the reactants (II) and (III) are coupled together in a suitable inert organic solvent such as tetrahydrofuran, benzene, toluene or N-methylpyrrolidine. The reaction is  
10 performed in the presence of an added base such as sodium hydride, butyl lithium or lithium diisopropylamide. The reaction is conducted at a suitable temperature, normally between room temperature and the boiling point of the solvent. The reaction is generally continued for a period of about one hour to one week, or until analysis indicates that formation of the required product is complete.

15

In process (b), the compound is oxidised using one equivalent of a suitable oxidising agent such as those known in the art for the oxidation of sulphides into sulfoxides. A preferred oxidant is oxone. The reaction is generally conducted at ambient temperature and in a suitable solvent such as methanol or aqueous acetonitrile.

20

Compounds of formula (I) and intermediate compounds thereto may be prepared as such or in protected form. Protecting groups that are suitable for particular functional groups and details of processes for adding and removing such protecting groups are, in general, well known in the art. See, for example, "Protective Groups in Organic Synthesis", 3rd Edition  
25 (1999) by Greene and Wuts.

25

The present invention includes compounds of formula (I) in the form of salts. Suitable salts include those formed with organic or inorganic acids or organic or inorganic bases. Such salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically  
30 acceptable acids or bases may be of utility in the preparation and purification of the compound in question. Thus, preferred acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic,


30

succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids. Preferred base addition salts include those in which the cation is sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, choline, ethanolamine or diethylamine.

- 5 Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxan, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed *in vacuo* or by freeze drying.
- 10 The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.


- Sulphone derivatives of formula (II) may be prepared by oxidation of the corresponding sulphides of formula (IV) using two or more equivalents of an oxidising agent such as
- 15 oxone.

In general, compounds of formula (IV) may be prepared using known methods that will be readily apparent to the man skilled in the art. Some such methods are illustrated in Schemes 1 to 3:




11


Scheme 1



Scheme 2



Scheme 3



Intermediate compounds may be used as such or in protected form. Protecting groups and details of processes for their removal may be found by reference to the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

5

The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.

10

The compounds of formula (I) may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC. Alternatively, the various optical isomers may be prepared directly using optically active starting materials.

15

Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.

The compounds of formula (I), and their pharmaceutically acceptable salts are useful because they possess pharmacological activity as antagonists of the CX<sub>3</sub>CR1 receptor. In particular, when compared to similar sulphide derivatives disclosed in WO 01/25242, the ether  
5 [formula (I); X = O] and sulfoxide [formula (I); X = S(O)] derivatives of the present invention possess significantly improved solubility profiles.

In one aspect the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a medicament.

10

In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial.

15

In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis or pain.

20

According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically  
25 acceptable salt thereof.

There is also provided a method of treating, or reducing the risk of, neurodegenerative disorders, demyelinating disease, atherosclerosis or pain in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the

person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

5 In another aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of diseases or conditions in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial.

10 In another aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis or pain.

15

The compounds of formula (I) and their pharmaceutically acceptable salts are indicated for use in the treatment or prophylaxis of diseases or conditions in which modulation of activity at the CX<sub>3</sub>CR1 receptor is desirable. In particular, the compounds are indicated for use in the treatment of neurodegenerative disorders or demyelinating disease in mammals including man. The compounds are also indicated to be useful in the treatment of pain, rheumatoid arthritis, osteoarthritis, stroke, atherosclerosis and pulmonary arterial hypertension.

25 Conditions that may be specifically mentioned are: neurodegenerative diseases and dementia disorders, for example, Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy, Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, for example, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and plexopathies; CNS demyelination, for example, acute disseminated/haemorrhagic encephalomyelitis and subacute sclerosing panencephalitis; neuromuscular disorders, for example, myasthenia gravis

30

and Lambert-Eaton syndrome; spinal disorders, for example, tropical spastic paraparesis and stiff-man syndrome; paraneoplastic syndromes, for example, cerebellar degeneration and encephalomyelitis; CNS trauma; and migraine.

- 5 Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly  
10 susceptible to developing the disease or condition.

The compounds of the invention are also indicated for use in the treatment of inflammatory bowel disease (IBD), for example, Crohn's disease and ulcerative colitis, by inducing remission and/or maintaining remission of IBD.

15

For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.

20

The compounds of formula (I) and pharmaceutically acceptable derivatives thereof, may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, intravenous, topical or other parenteral routes.

25

Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a  
30 compound of formula (I), or a pharmaceutically acceptable salt thereof.

30



There is also provided a process for the preparation of such a pharmaceutical composition that comprises mixing the ingredients.

The invention is illustrated, but in no way limited, by the following examples:

5

### General Procedures

Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Gemini 7 Tesla 300 MHz instrument, or a Bruker Avance 400 MHz instrument using the solvent indicated.

10 Chemical shifts are given in ppm down- and upfield from tetramethylsilane (TMS).

Resonance multiplicities are denoted s, d, t, m, br and app for singlet, doublet, triplet, multiplet, broad and apparent, respectively. Mass spectra (MS) were recorded on a Finnigan SSQ7000 TSP or a Finnigan SSQ710 DI/EI instrument, or on a single quadrupole mass spectrometer, ZMD (Waters), using an electrospray ion source operated in a positive

15 mode. The ion spray voltage was +3 kV and the mass spectrometer was scanned from  $m/z$  100 – 900 with a scan time of 0.85s. LC-MS was performed with a Waters 2790 LC-system equipped with a Waters Xterra<sup>TM</sup> MS C<sub>8</sub> (2.5  $\mu$ m x 30 mm) column, a Waters 996 photodiode array detector and a Micromass ZMD. High pressure liquid chromatography (HPLC) assays were performed using a Hewlett Packard 1100 Series HPLC system

20 equipped with a Zorbax SB-C<sub>8</sub> (4.6 mm x 15 cm) column. Preparative high pressure liquid chromatography (prep HPLC) separations were performed on an automated Gilson (model 170) using an Xterra C<sub>18</sub> (19 mm x 30 cm) column, and using a gradient of A (water 95%, containing NH<sub>4</sub>OAc (0.01 M), and 5% CH<sub>3</sub>CN) and B (CH<sub>3</sub>CN) as eluent. Column chromatography was performed using silica gel 60 (230-400 mesh ASTM, Merck) and thin

25 layer chromatography (TLC) was performed on TLC precoated plates, silica gel 60 F<sub>254</sub> (Merck).

**Example 1**                    5-(Benzyloxy)-7-([1*R*]-1-(hydroxymethyl)-3-methylbutylamino)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

30

(a) (2R)-2-({2-Chloro-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl}amino)-4-methylpentan-1-ol

(2R)-2-({2-Amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl}amino)-4-methylpentan-1-ol (WO 00/09511) (20.0 g, 47 mmol) was dissolved in conc. HCl (750 mL). CH<sub>3</sub>CN (600 mL) and water (350 mL) were added and the mixture was cooled to 0 °C. A solution of NaNO<sub>2</sub> (3.24 g, 94 mmol) in water (20 mL) was then added portionwise, and the mixture was stirred at 0 °C for 1.5 h. The yellow solid which had formed was collected by filtration, washed with water and dried to give 16.3 g (88%) of the title compound as a pale yellow solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 8.15 (d, 1H), 7.42-7.28 (m, 2H), 7.20-7.10 (m, 1H), 4.50 (b s, 1H), 4.46 (app t, 2H), 4.38-4.25 (m, 1H), 3.42 (app q, 2H), 1.67-1.54 (m, 1H), 1.53-1.42 (m, 1H), 1.41-1.32 (m, 1H), 0.88 (d, 3H), 0.83 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 445 [M+H]<sup>+</sup>.

(b) (2R)-2-({5-[(2,3-Difluorobenzyl)thio]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl}amino)-4-methylpentan-1-ol

The product from step (a) (10.75 g, 24.4 mmol) was dissolved in MeOH and solid potassium hydroxide (2.74 g, 48.8 mmol) was added. The mixture was heated to 55 °C for 1 h, cooled to RT and then neutralized with 2N HCl. MeOH was removed by evaporation *in vacuo*, water was added to the residue and the crude product was collected by filtration. Recrystallization from CH<sub>3</sub>CN gave title compound (9.25 g; 88%) as a pale orange solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.60 (d, 1H), 7.40-7.28 (m, 2H), 7.20-7.10 (m, 1H), 4.74 (t, 1H), 4.44 (app q, 2H), 4.29 (b s, 1H), 4.16 (s, 3H), 3.9-3.35 (m, 2H, partially under the water peak), 1.65-1.52 (m, 1H), 1.50-1.32 (m, 2H), 0.87 (d, 3H), 0.82 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 441 [M+H]<sup>+</sup>.

(c) 5-[(2,3-Difluorobenzyl)thio]-7-{{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one

The product from step (b) (8.83 g, 20.0 mmol) was suspended in dioxane (300 mL). Conc. HCl (1.5 mL) and water (1 mL) were added and the mixture was heated to 50 °C for 15 h. Solvents were removed *in vacuo* and the residue was suspended in CH<sub>3</sub>CN (300 mL). The

off white solid was filtered off, washed with CH<sub>3</sub>CN and dried to afford 7.92 g (90%) of the title compound.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.43 (br s, 1H), 7.45-7.27 (m, 3H), 7.20-7.08 (m, 1H), 4.46 (b s, 2H), 4.39 (1H, under the water peak), 4.26 (br s, 1H), 3.42-3.28 (m, 2H), 1.62-1.50 (m,

1H), 1.48-1.39 (m, H), 1.38-1.28 (m, 1H), 0.86 (d, 3H), 0.81 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 427 [M+H]<sup>+</sup>.

(d) 5-[(2,3-Difluorobenzyl)sulfonyl]-7-[[1(R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The product from step (c) (2.0 g, 4.68 mmol) was dissolved in CH<sub>3</sub>CN (240 mL) and water (160 mL). Potassium peroxymonosulfate (Oxone, 6.32 g, 10.30 mmol) was added and the resulting inhomogeneous mixture was stirred at RT for 24 h. Sodium thiosulphate solution was added and the CH<sub>3</sub>CN was evaporated *in vacuo*. The residue was poured onto ice and the precipitate was collected by filtration, washed with water and dried *in vacuo* at 40 °C

overnight resulting in 1.76 g (82%) of the title compound as an off-white solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 13.10 (br s, 1H), 7.52-7.40 (m, 2H) 7.28-7.18 (m, 2H), 5.0-4.85 (app t, 2H), 4.77 (br s, 1H), 4.29 (br s, 1H), 3.34 (br s, 2H), 1.65-1.51 (m, 1H), 1.50-1.31 (m, 2H), 0.88 (d, 3H), 0.85 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 459 [M+H]<sup>+</sup>.

(e) 5-(Benzyloxy)-7-[[1(R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Solid sodium hydride (17 mg, 0.7 mmol) was added to a stirred solution of benzyl alcohol (76 mg, 0.7 mmol) in dry benzene (5 mL) at 0 °C. The solution was allowed to reach RT over 15 min. The product from step (d) (46 mg, 0.1 mmol) was added as a solid, and the mixture was heated to reflux for 1 h. After cooling to RT, the reaction was quenched by the addition of of saturated aqueous NH<sub>4</sub>Cl (1 mL). The mixture was partitioned between THF (10 mL) and water (10 mL). The organic phase was separated, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated *in vacuo*. The oily residue was purified by preparative HPLC, to give the title compound as a crystalline solid (6.0 mg, 16% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.05 (br s, 1H), 7.52-7.24 (m, 5H), 5.95 (d, 1H), 5.02 (s, 2H), 4.77-4.29 (m, 2H), 3.38-3.30 (m, 2H), 1.63 (m, 1H), 1.50-1.32 (m, 2H), 0.89 (d, 3H), 0.83 (d, 3H);  
MS (ESI<sup>+</sup>) *m/z* 375 [M+H]<sup>+</sup>.

5

The compounds of Examples 2 and 3 were prepared using the general method of Example 1, step (e), but replacing benzyl alcohol with the appropriate alcohol.

**Example 2**                    7-[[1*R*]-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

10

Off-white solid (4.8 mg, 12% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.75 (br s, 1H), 7.44-7.24 (m, 2H), 6.91 (s, 1H), 6.84 (d, 1H), 5.90 (d, 1H), 5.22 (s, 2H), 4.70-4.31 (m, 2H), 3.48 (s, 3H), 3.40-3.30 (m, 2H), 1.62 (m, 1H), 1.50-1.31 (2H), 0.88 (d, 3H), 0.83 (d, 3H);

15 MS (ESI<sup>+</sup>) *m/z* 405 [M+H]<sup>+</sup>.

**Example 3**                    7-[[1*R*]-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-(2-phenylethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Off-white solid (8.1 mg, 21% yield).

20 

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.87 (br s, 1H), 7.44-7.16 (m, 5H), 5.90 (d, 1H), 4.81 (t, 2H), 4.58-4.30 (m, 2H), 3.42-3.32 (m, 2H), 3.29 (t, 2H), 1.63 (m, 1H), 1.52-1.31 (m, 2H), 0.88 (d, 3H), 0.80 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 389 [M+H]<sup>+</sup>.

25 **Example 4**                    5-(Benzyloxy)-7-[[1*R*]-1-(hydroxymethyl)butyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

(a) (2*R*)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]pentan-1-ol

30 

5-(Benzylthio)-7-chloro[1,3]thiazolo[4,5-*d*]pyrimidin-2-amine (WO 00/09511) (2.03 g, 6.57 mmol) was dissolved in 1-methyl-2-pyrrolidinone (NMP) (12 mL). *N*-Ethyl-*N,N*-diisopropylamine (DIPEA) (2.25 mL, 13.1 mmol) and 2-amino-(2*R*)-1-pentanol (1.19 g,

11.5 mmol) were added and the mixture was heated to 110 °C for 4 days. After cooling to RT, the mixture was poured into water (200 mL). The yellow solid was collected by filtration, washed with water and used for the next step without further purification (yield 80%).

5 MS (ESI<sup>+</sup>) *m/z* 376 [M+H]<sup>+</sup>.

(b) (2R)-2-[[5-(Benzylthio)-2-chloro[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino}pentan-1-ol

The product from step (a) (2.46 g, 6.57 mmol) was dissolved in CH<sub>3</sub>CN (70 mL). Sodium nitrite (1.36 g, 19.71 mmol) and conc. HCl (25 mL) were added at 0 °C and the reaction mixture was stirred at 0 °C for 3 h. The reaction mixture was diluted with water and extracted with EtOAc (3 x 60 mL), and the combined organic phases were dried, filtered and concentrated to give 2.59 g (quantitative yield) of the title compound as a yellow solid. MS (ESI<sup>+</sup>) *m/z* 395 [M+H]<sup>+</sup>.

15

(c) (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino}pentan-1-ol

The product from step (b) (2.59 g, 6.57 mmol) was dissolved in MeOH (80 mL). KOH (737 mg, 13.14 mmol) was added and the reaction mixture was stirred for 1.5 h at 50 °C. After cooling to RT, the MeOH was removed under reduced pressure, the residue was diluted with brine and extracted with EtOAc (3 x 50 mL), and the combined organic phases were dried, filtered and concentrated to give 2.56 g (quantitative yield) of title compound as a yellow solid.

MS (ESI<sup>+</sup>) *m/z* 391 [M+H]<sup>+</sup>.

25

(d) 5-(Benzylthio)-7-[[[(1R)-1-(hydroxymethyl)butyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The product from step (c) (2.56 g, 6.57 mmol) was dissolved in dioxane (50 mL). Conc. HCl (544 µL, 6.57 mmol) was added and the reaction mixture was stirred for 4 h at 50 °C. After cooling to RT, about half of the dioxane was removed under reduced pressure. The residue was diluted with brine, extracted with EtOAc (3 x 50 mL), and the combined

30

organic phases were dried and concentrated to give 2.2 g (89%) of the title compound as a brown solid. It was used in the subsequent step without further purification.

MS (ESI<sup>+</sup>)  $m/z$  377 [M+H]<sup>+</sup>.

5 (e) 5-(Benzylsulfonyl)-7-[[[(1R)-1-(hydroxymethyl)butyl]amino]][1,3]thiazolo[4,5-  
d]pyrimidin-2(3H)-one

The product from step (d) (1360 mg, 3.61 mmol) was dissolved in CH<sub>3</sub>CN (85 mL) and water (56 mL). Potassium peroxymonosulfate (Oxone, 4 g, 6.51 mmol) was added and the resulting inhomogeneous mixture was stirred at RT for 24 h. The reaction mixture was  
10 concentrated to about one fifth of the original volume and extracted with EtOAc (3 x 40 mL). The combined organic phases were dried, filtered and concentrated to give 1.46 g (99%) of the title compound as a pale yellow powder.

MS (ESI<sup>+</sup>)  $m/z$  409 [M+H]<sup>+</sup>.

15 (f) 5-(Benzyloxy)-7-[[[(1R)-1-(hydroxymethyl)butyl]amino]][1,3]thiazolo[4,5-d]pyrimidin-  
2(3H)-one

NaH (17 mg, 0.71 mmol) was added to a slurry of the product from step (e) (29 mg, 0.071 mmol) and benzyl alcohol (77 mg, 0.71 mmol) in dry benzene (0.5 mL) at RT. The reaction mixture was stirred for a few minutes at RT, and then heated to 40 °C for 50 min.  
20 After cooling to RT, the reaction mixture was quenched with water (0.1 mL) and concentrated. The residue was dissolved in DMSO (1 mL) and then purified by preparative HPLC to give 13.5 mg (52.7%) of the title compound as an off-white solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.25 (s, 1H), 7.44-7.29 (m, 5H), 5.29 (d, 1H), 5.25 (d, 1H), 4.65 (t, 1H), 4.13 (br s, 1H), 3.46-3.40 (m, 1H), 1.61-1.51 (m, 1H), 1.46-1.14 (m, 3H), 0.84 (t, 3H);  
25

MS (ESI<sup>+</sup>)  $m/z$  361 [M+H]<sup>+</sup>.

**Example 5** 7-[[[(1R)-1-(Hydroxymethyl)butyl]amino]-5-[[[(1S)-1-phenylethyl]oxy]][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one

30 The product from Example 4, step (e) (62 mg, 0.15 mmol) and (S)-1-phenylethanol (185 mg, 1.51 mmol) were dissolved in dry THF (2 mL) at RT, and n-BuLi (1.6M in hexanes, 0.85 mL, 1.36 mmol) was added. After stirring for 15 min at RT, the reaction mixture was

heated to 50 °C for 24 h, cooled to RT and concentrated. The residue obtained was dissolved in DMSO (1 mL) and then purified by preparative HPLC to give 11.4 mg (20%) of the title compound as a slightly yellowish oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.41-7.23 (m, 5H), 5.90 (q, 1H), 4.60 (br d, 1H), 4.21-4.12 (m, 1H), 3.48 (dd, 1H), 3.42 (dd, 1H), 2.09 (s, 3H), 1.65-1.37 (m, 4), 0.97 (t, 3H);  
MS (ESI<sup>+</sup>) *m/z* 375 [M+H]<sup>+</sup>.

**Example 6**      *N*-(3-{[(7-{[(1*R*)-1-(Hydroxymethyl)butyl]amino}-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl}phenyl)-*N*-methylmethanesulfonamide

(a) Methyl 3-[methyl(methylsulfonyl)amino]benzoate

Solid NaOMe (260 mg, 4.79 mmol) was added to a solution of methyl 3-[(methylsulfonyl)amino]benzoate (Laurence, C.; Berthelot, M.; Lucon, M.; Tsuno, Y. *Spectrochim. Acta Part A* **1982**, 38, 791-796) (500 mg, 2.18 mmol) and MeI (0.4 mL, 6.42 mmol) in a mixture of THF (15 mL) and MeOH (15 mL). After 1 h at RT, the reaction mixture was heated to 50 °C for 1.5 h. The reaction mixture was cooled to RT, diluted with brine (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated, and the residue was purified by preparative HPLC to give 436 mg (82.2%) of the title compound as a white solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.00-7.91 (m, 2H), 7.60 (d, 1H), 7.44 (t, 1H), 3.89 (s, 3H), 3.33 (s, 3H), 2.83 (s, 3H);  
MS (ESI<sup>+</sup>) *m/z* 244 [M+H]<sup>+</sup>.

(b) *N*-[3-(Hydroxymethyl)phenyl]-*N*-methylmethanesulfonamide

Lithium borohydride (195 mg, 8.96 mmol) was added to a solution of the product from step (a) (436 mg, 1.79 mmol) in THF (25 mL). The reaction mixture was stirred for 2 h at RT, and then 20 h at 50 °C. After cooling to RT, the mixture was diluted with brine (30 mL) and extracted with EtOAc (2 x 40 mL), dried over MgSO<sub>4</sub>, and concentrated. The residue was purified by flash chromatography (0-5% MeOH in CHCl<sub>3</sub>) to give 360 mg (93%) of the title compound as colourless oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.31-7.27 (m, 2H), 7.21-7.16 (m, 2H), 4.57 (s, 2H), 3.22 (s, 3H), 2.75 (s, 3H);  
MS (ESI<sup>+</sup>) *m/z* 216 [M+H]<sup>+</sup>.

- 5 (c) *N*-(3-[[7-[[1*R*]-1-(Hydroxymethyl)butyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl]oxy)methyl]phenyl)-*N*-methylmethanesulfonamide  
n-BuLi (0.175 mL, 0.28 mmol, 1.6M in hexanes) was added to a stirred solution of *N*-[3-(hydroxymethyl)phenyl]-*N*-methyl-methanesulfonamide (from step (b), 60 mg, 0.28 mmol) and the product from Example 4, step (e) (36.5 mg, 0.089 mmol) in dry THF (1 mL). The  
10 resulting mixture was stirred at 50 °C for 18 h. After cooling to RT, the reaction mixture was concentrated, and the residue dissolved in DMSO (0.5 mL) and then purified by preparative HPLC to give 4 mg (9.6%) of the title compound as a white solid.  
MS (ESI<sup>+</sup>) *m/z* 468 [M+H]<sup>+</sup>.

- 15 **Example 7** *N*-(3-[[7-[[1*R*]-1-(Hydroxymethyl)-2-methylpropyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl]oxy)methyl]phenyl)-methanesulfonamide

- 20 (a) (2*R*)-2-[[5-(Benzylthio)-2-chloro[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-3-methylbutan-1-ol

- A suspension of (2*R*)-2-[[2-amino-5-(benzylthio)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-3-methylbutan-1-ol (WO 02/76990) (4.00 g, 10.7 mmol) in conc. HCl (150 mL) and CH<sub>3</sub>CN (110 mL) was cooled to 0 °C. Sodium nitrite (1.47 g, 21.3 mmol) was added and the solution was stirred at 0 °C for 1 h. Water (640 mL) was added and the resulting  
25 mixture was stirred for 15 min followed by filtration of the precipitate. The solid was washed with water and dried *in vacuo* over P<sub>2</sub>O<sub>5</sub> at RT for 48 h resulting in 3.54 g (84%) of the title compound as a pink solid.

- <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.10 (d, 1H), 7.44-7.39 (m, 2H), 7.32-7.26 (m, 2H), 7.25-7.19 (m, 1H), 4.81-4.49 (br s, 1H), 4.39 (d, 1H), 4.34 (d, 1H), 4.14-4.05 (m, 1H), 3.57-3.45 (m, 2H),  
30 1.98-1.87 (m, 1H), 0.92-0.80 (m, 6H);  
MS (ESI<sup>+</sup>) *m/z* 395 [M+H]<sup>+</sup>.



(b) (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-3-methylbutan-1-ol

Using the product of step (a) as starting material, the title compound was obtained as a beige solid (67%) by following the general method described in Example 1, step (b).

- 5 <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.61-7.54 (m, 1H), 7.45-7.36 (m, 2H), 7.35-7.19 (m, 3H), 4.66-4.58 (m, 1H), 4.41-4.30 (m, 2H), 4.19-4.02 (m, 4H), 3.58-3.43 (m, 2H), 1.97-1.86 (m, 1H), 0.92-0.80 (m, 6H);  
MS (ESI<sup>+</sup>) *m/z* 391 [M+H]<sup>+</sup>.

10 (c) 5-(Benzylthio)-7-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

Using the product of step (b) as starting material, the title compound was obtained as a light orange solid (68%) by following the general method described in Example 1, step (c).

- 15 <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.36 (br s, 1H), 7.43-7.38 (m, 2H), 7.32-7.19 (m, 4H), 4.57 (app t, 1H), 4.33 (d, 1H), 4.28 (d, 1H), 4.08-3.97 (m, 1H), 3.54-3.41 (m, 2H), 1.93-1.83 (m, 1H), 0.87-0.79 (m, 6H);  
MS (ESI<sup>+</sup>) *m/z* 377 [M+H]<sup>+</sup>.

20 (d) 5-(Benzylsulfonyl)-7-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

Using the product of step (c) as starting material, the title compound was obtained as a pale yellow powder (99%) by following the general method described in Example 1, step (d).

MS (ESI<sup>+</sup>) *m/z* 409 [M+H]<sup>+</sup>.

25 (e) N-(3-[[[(7-[[[(1R)-1-(Hydroxymethyl)-2-methylpropyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl]oxy)methyl]phenyl)methanesulfonamide

Solid sodium hydride (18 mg, 0.75 mmol) was added to a stirred solution of the product of step (d) (28.5 mg, 0.069 mmol) and *N*-[3-(hydroxymethyl)phenyl]-methanesulfonamide (WO 01/90070) (35 mg, 0.17 mmol) in a mixture of toluene (0.2 mL) and 1-methyl-2-pyrrolidinone (0.2 mL) at RT. The reaction mixture was stirred for 16 h at 50 °C. After cooling to RT, the reaction mixture was quenched with water (0.1 mL) and concentrated.

30

The residue was dissolved in DMSO (1 mL), and purified by preparative HPLC to give 4.5 mg (14.3%) of the title compound as an off-white solid.

MS (ESI<sup>+</sup>)  $m/z$  454 [M+H]<sup>+</sup>.

5 **Example 8** 5-(Benzyloxy)-7-[[1-(hydroxymethyl)cyclopentyl]amino]-[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

a) (1-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]cyclopentyl)methanol

- 10 The title compound was prepared using the general method of Example 4, step (a), but replacing 2-amino-(2*R*)-1-pentanol with cycloleucinol. The yellow solid was collected by filtration, washed with water and used for the next step without further purification.
- MS (ESI<sup>+</sup>)  $m/z$  388 [M+H]<sup>+</sup>.

15 b) 5-(Benzylthio)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

- The product from step (a) (1.2 g, 3.1 mmol) was suspended in water (150 mL), DMSO (10 mL) was added, and the mixture was heated to 80 °C. Solid sodium nitrite (2.14 g, 31 mmol) was added in one portion and the mixture was heated at 80 °C for 3 h. After cooling
- 20 to RT, acetic acid (10 mL) was added, and the white precipitate was collected by filtration. Purification of the crude product by flash column chromatography (EtOAc:CH<sub>2</sub>Cl<sub>2</sub> 30:70) afforded the title compound (288 mg, 24% over two steps) as a white solid.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.45 (s, 1H), 7.44-7.22 (m, 5H), 7.0 (br s, 1H), 4.77 (t, 1H), 4.33 (s, 2H), 3.63 (d, 2H), 1.98 (m, 2H), 1.75 (m, 2H), 1.60 (m, 2H), 1.49 (m, 2H);

- 25 MS (ESI<sup>+</sup>)  $m/z$  389 [M+H]<sup>+</sup>.

c) 5-(Benzylsulfonyl)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

- The title compound was prepared from the product of step (b), by following the procedure used in Example 1, step (d), and was obtained as an off-white solid in 86% yield.
- 30

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.45 (s, 1H), 7.45-7.22 (m, 5H), 7.11 (br s, 1H), 4.93 (t, 1H), 4.82 (s, 2H), 3.60 (d, 2H), 1.98 (m, 2H), 1.72 (m, 2H), 1.60 (m, 2H), 1.46 (m, 2H);

MS (ESI<sup>+</sup>)  $m/z$  421 [M+H]<sup>+</sup>.

(d) 5-(Benzyloxy)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-  
d]pyrimidin-2(3H)-one

5 Solid sodium hydride (17 mg, 0.7 mmol) was added to a stirred mixture of benzyl alcohol (ca. 850  $\mu$ L) and toluene (ca. 150  $\mu$ L) at 60 °C. The solution was stirred at that temperature for 15 min, then the product of step (c) (42 mg, 0.1 mmol; 1 eq) was added as a solid in one portion, and the mixture was stirred at 60 °C for 1 h. After cooling to RT, the reaction was quenched by addition of saturated aqueous NH<sub>4</sub>Cl (1 mL). The mixture was then  
10 partitioned between THF (10 mL) and water (10 mL). The organic phase was separated, dried, and concentrated. The residual oil was then triturated with EtOAc:hexane 1:1 (about 15 mL). The residue was purified by preparative HPLC to give the title compound as an off-white crystalline solid (16% yield).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  12.50 (s, 1H), 7.44-7.22 (m, 5H), 7.11 (br s, 1H), 5.13 (s, 2H), 4.90  
15 (t, 1H), 3.71 (d, 2H), 1.98 (m, 2H), 1.72 (m, 2H), 1.60 (m, 2H), 1.45 (m, 2H);  
MS (ESI<sup>+</sup>)  $m/z$  373 [M+H]<sup>+</sup>.

The compounds of Examples 9 to 16 were prepared using the general method of Example 8, step (d), but replacing benzyl alcohol with the appropriate alcohol.

20

**Example 9** 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(2-  
methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

Off-white solid (6.5 mg, 17% yield).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  12.55 (s, 1H), 7.40 (d, 1H), 7.35-7.22 (m, 3H), 7.08 (br s, 1H), 5.13  
25 (s, 2H), 4.85 (t, 1H), 3.73 (d, 2H), 2.33 (s, 3H), 2.00 (m, 2H), 1.72 (m, 2H), 1.63 (m, 2H),  
1.45 (m, 2H);

MS (ESI<sup>+</sup>)  $m/z$  387 [M+H]<sup>+</sup>.

**Example 10** 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(3-  
methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

30

Off-white solid (6.5 mg, 17% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.52 (s, 1H), 7.37-7.20 (m, 3H), 7.05 (br s, 1H), 6.92 (d, 1H), 5.19 (s, 2H), 4.82 (t, 1H), 3.70 (d, 2H), 2.38 (s, 3H), 2.00 (m, 2H), 1.76 (m, 2H), 1.63 (m, 2H), 1.43 (m, 2H);  
MS (ESI<sup>+</sup>) *m/z* 387 [M+H]<sup>+</sup>.

5

**Example 11**      5-[(2-Chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Off-white solid (5.7 mg, 14% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.42 (s, 1H), 7.31-7.05 (m, 4H), 7.05 (br s, 1H), 5.09 (s, 2H), 4.80 (t, 1H), 3.70 (d, 2H), 1.93 (m, 2H), 1.75 (m, 2H), 1.60 (m, 2H), 1.43 (m, 2H);  
MS (ESI<sup>+</sup>) *m/z* 406 [M+H]<sup>+</sup>.

10

**Example 12**      5-[(3-Chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Off-white solid (6.1 mg, 15% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.48 (s, 1H), 7.30 (s, 1H), 7.21-7.05 (m, 3H), 7.01 (br s, 1H), 5.12 (s, 2H), 4.81 (t, 1H), 3.75 (d, 2H), 1.97 (m, 2H), 1.75 (m, 2H), 1.63 (m, 2H), 1.41 (m, 2H);  
MS (ESI<sup>+</sup>) *m/z* 406 [M+H]<sup>+</sup>.

15

**Example 13**      5-[(4-Chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Off-white solid (6.1 mg, 15% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.28 (s, 1H), 7.37 (d, 2H), 7.14 (d, 2H), 6.90 (br s, 1H), 5.22 (s, 2H), 4.88 (t, 1H), 3.75 (d, 2H), 1.99 (m, 2H), 1.75 (m, 2H), 1.64 (m, 2H), 1.40 (m, 2H);  
MS (ESI<sup>+</sup>) *m/z* 406 [M+H]<sup>+</sup>.

25

**Example 14**      7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Off-white solid (4.8 mg, 12% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.17 (s, 1H), 7.34 (d, 1H), 7.20 (m, 1H), 6.97-6.89 (3H), 5.31 (s, 2H), 4.78 (t, 1H), 3.90 (s, 3H), 3.75 (d, 2H), 1.96 (m, 2H), 1.75 (m, 2H), 1.67 (m, 2H), 1.41 (m, 2H);

30

MS (ESI<sup>+</sup>)  $m/z$  403 [M+H]<sup>+</sup>.

**Example 15**      7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

5 Off-white solid (7.2 mg, 18% yield).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.30 (s, 1H), 7.31-7.25 (m, 2H), 7.06 (d, 1H), 6.92 (s, 1H), 6.88 (br s, 1H), 5.31 (s, 2H), 4.78 (t, 1H), 3.95 (s, 3H), 3.70 (d, 2H), 1.99 (m, 2H), 1.75 (m, 2H), 1.63 (m, 2H), 1.40 (m, 2H);

MS (ESI<sup>+</sup>)  $m/z$  403 [M+H]<sup>+</sup>.

10

**Example 16**      4-[[[7-[[1-(Hydroxymethyl)cyclopentyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl)oxy]methyl]benzonitrile

Off-white solid (5.2 mg, 13% yield).

15 <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.28 (s, 1H), 7.57 (d, 2H), 7.44 (d, 2H), 6.90 (br s, 1H), 5.37 (s, 2H), 4.80 (t, 1H), 3.75 (d, 2H), 2.02 (m, 2H), 1.73 (m, 2H), 1.60 (m, 2H), 1.40 (m, 2H);  
MS (ESI<sup>+</sup>)  $m/z$  398 [M+H]<sup>+</sup>.

**Example 17**      (*R,S*)-7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-(1-phenylethoxy)-thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

20 *n*-BuLi (0.405 mL, 0.648 mmol, 1.6M in hexanes) was added to a stirred solution of racemic 1-phenyl-ethanol (87 mg, 0.72 mmol) in dry THF (0.2 mL) at RT. After 5 min stirring this mixture was added dropwise to the product of Example 8, step (c) (15.2 mg, 0.036 mmol) in dry THF (0.4 mL). When the addition was finished, the reaction mixture was stirred at 50 °C for 18 h. After cooling to RT, the reaction mixture was concentrated,  
25 and the residue dissolved in DMSO (1 mL) and then purified by preparative HPLC to give 3.3 mg (24%) of the title compound as a white solid.  
MS (ESI<sup>+</sup>)  $m/z$  387 [M+H]<sup>+</sup>.

**Example 18**      7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[[1*S*]-1-phenylethyl]oxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

30

The title compound was prepared (7% yield) using the general method of Example 17, but replacing racemic 1-phenyl-ethanol with (1*S*)-1-phenyl-ethanol.

MS (ESI<sup>+</sup>)  $m/z$  387 [M+H]<sup>+</sup>.

**Example 19** 5-([2-(3-Chlorophenyl)-(R<sub>S</sub>,S<sub>S</sub>)-ethyl]sulfinyl)-7-([(1R)-1-(hydroxymethyl)-3-methylbutyl]amino)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

(a) (2R)-2-[2-Chloro-5-[2-chloro-7-((1R)-1-hydroxymethyl-3-methyl-butylamino)-thiazolo[4,5-*d*]pyrimidin-5-yl]disulfanyl]-thiazolo[4,5-*d*]pyrimidin-7-ylamino]-4-methyl-pentan-1-ol

To a slurry of (2R)-2-[[2-amino-5-mercapto[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methylpentan-1-ol (WO 02/76990) (7.50 g, 25 mmol) in a mixture of conc. HCl and CH<sub>3</sub>CN (1:1, 300 mL) at 0 °C was added dropwise a solution of sodium nitrite (5.19 g, 75 mmol) in water (25 mL). The reaction mixture was stirred for 18 h at 0-5 °C, and then poured onto ice (500 mL), and extracted with EtOAc with any remaining solid being filtered off. The combined organic phases were washed sequentially with saturated NaCl and saturated aqueous NaHCO<sub>3</sub> solution. The organic phase was dried and evaporated and the solid previously filtered off was added to this. The total solid was slurried in EtOAc which, after filtration, provided the title compound (6.3 g, 80%) as a pale yellow solid.

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>; integrals are for the monomeric unit) δ 7.98 (d, 1H), 4.47 (t, 1 H), 3.99 (br s, 1 H), 3.19-3.14 (m, 2 H), 1.31-1.15 (m, 2 H), 1.02-0.94 (m, 1 H), 0.48 (d, 3 H), 0.30 (d, 3 H);

MS (ESI<sup>+</sup>)  $m/z$  635 [M+H]<sup>+</sup>.

(b) (2R)-2-[5-[7-((1R)-1-Hydroxymethyl-3-methyl-butylamino)-2-methoxy-thiazolo[4,5-*d*]pyrimidin-5-yl]disulfanyl]-2-methoxy-thiazolo[4,5-*d*]pyrimidin-7-ylamino]-4-methyl-pentan-1-ol

To a solution of the product from step (a) (3.0 g, 4.7 mmol) in dry MeOH (200 mL) was added KOH (0.53 g, 9.4 mmol) dissolved in dry MeOH (5 mL). The reaction was maintained at 0-5 °C for 18 h. The solvent was evaporated and the residue taken up in MeOH/EtOAc (1:1). This solution was rapidly chromatographed (silica, EtOAc) to provide the title compound (2.0 g, 68%) as a white solid.

MS (ESI<sup>+</sup>)  $m/z$  627 [M+H]<sup>+</sup>.

(c) 5-[7-[[1(R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one-5-yl]disulfanyl]-7-[[1(R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one

To a solution of the product from step (b) above (1.5 g, 2.4 mmol) in 1,4-dioxane (20 mL) was added a mixture of conc. HCl and water (40 mL, 1:1). The solution was then stirred at 45 °C for 18 h. The solvent was evaporated and the residue taken up in EtOAc (undissolved residue was filtered off and was found to be pure by LCMS). The solution was subjected to flash chromatography (silica, MeOH:EtOAc 5:95). The two samples were pooled together to give a white solid (600 mg, 42%, 75% pure by HPLC). This material was used without further purification in the ensuing reactions.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>; integrals are for the monomeric unit) δ 12.45 (s, 2H), 7.33 (d, 2H), 4.62 (t, 2H), 4.17 (br s, 2H), 1.48-1.31 (m, 4H), 1.25-1.14 (m, 2H), 0.72 (d, 6H), 0.56 (d, 6H);

MS (ESI<sup>+</sup>) *m/z* 599 [M+H]<sup>+</sup>.

(d) 1-(2-Bromoethyl)-3-chlorobenzene

To a solution of 2-(3-chlorophenyl)ethanol (1.06 g, 6.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at RT under nitrogen was added CBr<sub>4</sub> (1.98 g, 5.8 mmol) and PPh<sub>3</sub> (1.57 g, 5.8 mmol). After stirring at RT for 18 h the reaction mixture was concentrated and the residue diluted with Et<sub>2</sub>O (30 mL) resulting in precipitation of triphenylphosphine oxide. The ethereal solution was decanted, evaporated and purified *via* flash chromatography (silica, hexane) to provide 2-(3-chloro)phenylethyl bromide as a clear oil (57%).

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.39-7.22 (m, 3 H), 7.18-7.09 (m, 1 H), 3.63-3.51 (m, 2 H), 3.25-3.17 (m, 2 H);

<sup>13</sup>C NMR (100.6 MHz, DMSO-d<sub>6</sub>) δ 141.2, 134.6, 130.7, 129.3, 127.6, 127.3.

(e) 5-[2-(3-Chlorophenyl)ethyl]thio]-7-[[1(R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one

To a stirred solution of the product from step (c) above (30.0 mg, 0.05 mmol) in DMSO (0.5 mL) at RT was added NaBH<sub>4</sub> (5.6 mg, 0.125 mmol). Once effervescence had ceased, the product from step (d) above was added (20 mg, 0.09 mmol). The reaction was complete

after 18 h at RT. Purification was achieved using preparative HPLC to give a white solid (90%).

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.38-7.02 (m, 5 H), 6.08 (br s, 1 H), 4.29 (br s, 1 H), 3.60 (dd, 1 H), 3.49 (dd, 1 H), 3.26-3.18 (m, 2 H), 2.92 (t, 2 H), 1.63-1.55 (m, 1 H), 1.46-1.31 (m, 2 H), 0.82 (d, 3 H), 0.81 (d, 3 H);  
MS (ESI<sup>+</sup>) *m/z* 439 [M+H]<sup>+</sup>.

(f) 5-([2-(3-Chlorophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl)-7-([(1R)-1-(hydroxymethyl)-3-methylbutyl]amino)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

To a stirred solution of the product from step (e) above (15 mg, 0.025 mmol) in MeOH (2 mL) at RT was added potassium peroxymonosulfate (Oxone, 20.5 mg, 0.033 mmol). After 1.5 h the reaction was quenched by addition of water and saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. The aqueous phase was extracted with EtOAc, dried and evaporated. Purification was achieved using preparative HPLC to give the title compound as a white solid (mixture of two unresolved diastereoisomers, 1:1; 27%).

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.19-7.01 (m, 8 H), 6.99-6.98 (m, 2 H), 4.52 (t, 2 H), 4.07 (br s, 2 H), 2.87-2.80 (m, 2 H), 2.76-2.63 (m, 2 H), 1.27-1.20 (m, 2 H), 1.19-1.04 (m, 4 H), 0.70-0.66 (12 H, m);  
MS (ESI<sup>+</sup>) *m/z* 455 [M+H]<sup>+</sup>.

**Example 20**      5-([2-(2-Bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl)-7-([(1R)-1-(hydroxymethyl)-3-methylbutyl]amino)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

(a) 5-([2-(2-Bromophenyl)ethyl]thio)-7-([(1R)-1-(hydroxymethyl)-3-methylbutyl]amino)[1,3]thiazolo[4,5-*d*]pyrimidin-2(3H)-one

By following the procedure in Example 19, step (e), the title compound was obtained as a white solid in 58% yield from the reaction of the product of Example 19, step (c) with 1-(2-bromoethyl)-2-bromobenzene which, in turn, was prepared from 2-(2-bromophenyl)ethanol according to the procedure described in Example 19, step (d).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 7.55 (unresolved dd, 1H), 7.29 (dd, 1H), 7.25 (unresolved dt, 1H), 7.10 (dt, 1H), 5.1 (br s, 1H), 3.82 (dd, 1H), 3.67 (dd, 1H), 3.89 (app dt, 2H), 3.16 (t, 2H), 1.85-1.63 (m, 1H), 1.58-1.42 (m, 2H), 0.95 (d, 3H), 0.93 (d, 3H);



MS (ESI<sup>+</sup>) *m/z* 483, 485 [M+H]<sup>+</sup>.

(b) 5-[[2-(2-Bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

5 The title compound was obtained as a clear film in 62% yield (1:1 mixture of two unresolved diastereoisomers) from the product of step (a), by following the procedure described in Example 19, step (f).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ 7.50 (app dd, 1H), 7.27-7.21 (m, 2H), 7.12-7.06 (m, 1H), 4.97 (protons in the water peak, 3H) 4.45 (br s, 1H), 3.57-3.48 (m, 2H), 3.48-3.42 (m, 2H from one diastereomer), 3.37-3.30 (m, 2H from one diastereomer), 3.23-3.19 (m, 2H from one diastereomer), 3.07-3.01 (m, 2H from one diastereomer), 1.68-1.63 (m, 1H), 1.55-1.37 (m, 2H), 0.92 (d, 3H from one diastereomer), 0.90 (t, 6H from one diastereomer), 0.87 (d, 3H from one diastereomer);

MS (ESI<sup>+</sup>) *m/z* 499, 501 [M+H]<sup>+</sup>.

15

**Example 21**      5-[(2,3-Difluorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The title compound was obtained as a white solid in 41% yield (1:1 mixture of two unresolved diastereoisomers) starting from the product of Example 1, step (c) by following the general procedure described in Example 19, step (f).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.86 (b s, 1H), 7.68 (b s, 1H) 7.45-7.32 (m, 1H), 7.20-7.10 (m, 1H), 7.05-6.90 (m 1H), 4.77 (b s, 1H), 4.62-4.48 (app t, 1H), 4.38-4.20 (m, 2H), 3.90 (2H, partially under the water peak), 1.58 (b s, 1H), 1.50-1.30 (m, 2H), 0.88 (d, 3H), 0.84 (d, 3H);

25 MS (ESI<sup>+</sup>) *m/z* 443 [M+H]<sup>+</sup>.

**Example 22**      5-[Benzyl-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

30 (a) (2*R*)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino]-4-methylpentan-1-ol

To a suspension of (2*R*)-2-{{[5-(benzylthio)-2-bromo[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino}-4-methylpentan-1-ol (1.90 g, 4.19 mmol) (WO 02/76990) in anhydrous MeOH (45 mL) was added potassium hydroxide (0.52 g, 9.22 mmol). The mixture was stirred at RT for 35 minutes followed by the addition of conc. HCl to pH 5. The solvent was  
5 evaporated and the crude solid was partitioned between water and methylene chloride. The organic phase was washed twice with water, brine, dried (MgSO<sub>4</sub>), filtered, and the solvent was evaporated. The product was dried *in vacuo* at 35 °C for 2 h to give 1.72 g (quantitative yield) of the title compound as an orange solid.

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43 (d, 2H), 7.32-7.20 (m, 3H), 4.54 (d, 1H), 4.45-4.43 (m, 2H), 4.40-4.30 (m, 1H), 4.26 (s, 3H), 3.78-3.71 (m, 1H), 3.62-3.55 (m, 1H), 2.28 (t, 1H), 1.72-1.61 (m, 1H), 1.53-1.38 (m, 2H), 0.96-0.89 (m, 6H);  
10 MS (ESI<sup>+</sup>) *m/z* 405 [M+H]<sup>+</sup>.

(b) 5-(Benzylthio)-7-{{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one  
15

To a solution of the product from step (a) (1.72 g, 4.25 mmol) in 1,4-dioxane (50 mL) and water (1 mL) was added conc. HCl (0.91 mL). The mixture was heated at 45 °C for 15 h followed by evaporation of the solvent. A mixture of EtOAc/methylene chloride (5 mL, 30:70) was added and the solution was subjected to a stream of nitrogen gas for 2.5 h. The  
20 resulting solid was filtered off and washed with methylene chloride followed by EtOAc. The mother liquor was concentrated and flash chromatographed on silica (eluent EtOAc:methylene chloride 30:70). The two products were pooled resulting in 1.11 g (67% yield) of the title compound as a white solid.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.35 (br s, 1H), 7.43-7.39 (m, 2H), 7.31-7.19 (m, 4H), 4.36-4.23 (m, 3H), 3.45-3.28 (m, 1H) overlapping with H<sub>2</sub>O-signal, 1.63-1.51 (m, 1H), 1.46-1.31 (m, 2H), 0.88-0.78 (m, 6H);  
25 MS (ESI<sup>+</sup>) *m/z* 391 [M+H]<sup>+</sup>.

(c) 5-[Benzyl-(*R*<sub>S</sub>,*S*<sub>S</sub>)-sulfinyl]-7-{{[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one  
30

The title compound was obtained as a white solid in a 17% yield (1:1 mixture of two unresolved diastereoisomers) by following the method described in Example 19, step (f).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 12.82 (br s, 1H), 7.49 (br s, 1H), 7.34-7.26 (m, 3H), 7.17-7.10 (m, 2H), 4.76 (app t, 1H), 4.37 (dd, 2H from one diastereomer) overlapping with 4.30 (br s, 1H), 4.18 (dd, 2H from one diastereomer), 3.48-3.22 (m, 2H) overlapping with H<sub>2</sub>O-signal, 1.59 (br s, 1H), 1.49-1.32 (m, 2H), 0.93-0.82 (m, 6H);

5 MS (ESI<sup>+</sup>) *m/z* 407 [M+H]<sup>+</sup>.

The compounds of Examples 23 to 25 were prepared using the general method of Example 19, step (f). The precursor sulfides were prepared according to the method of Example 19, step (e), but replacing 1-(2-bromoethyl)-3-chlorobenzene with the appropriate benzylic  
10 halide, all of which are commercially available.

**Example 23**      5-[(2-Chlorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

15 (a) 5-[(2-Chlorobenzyl)thio]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The title compound was obtained as a white solid in 52% yield from the product of Example 19, step (c), and 1-chloro-2-(chloromethyl)benzene.

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.62-7.56 (m, 1H), 7.36-7.30 (m, 1H), 7.40-7.35 (m, 1H), 7.25-7.19 (m, 2H), 4.47 (dd, 2H) overlapping with 4.42 (br s, 1H), 3.56-3.47 (m, 2H), 1.71-1.59 (m, 1H), 1.56-1.46 (m, 1H), 1.45-1.36 (m, 1H), 0.92 (d, 3H), 0.89 (d, 3H);

20 MS (ESI<sup>+</sup>) *m/z* 425 [M+H]<sup>+</sup>.

(b) 5-[(2-Chlorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

25 The title compound was obtained as an off-white solid in a 30% yield (1:1 mixture of two unresolved diastereoisomers).

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.44 (d, 1H), 7.36-7.30 (m, 1H), 7.30-7.23 (m, 2H), 4.70 (dd, 2H from one diastereomer), 4.46 (br s, 1H), 4.37 (app t, 2H from one diastereomer), 3.58-3.47 (m, 2H), 1.72-1.60 (m, 1H), 1.55-1.38 (m, 2H), 0.97-0.88 (m, 6H);

30 MS (ESI<sup>+</sup>) *m/z* 441 [M+H]<sup>+</sup>.

**Example 24**      5-[(4-Chlorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

(a) 5-[(4-Chlorobenzyl)thio]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The title compound was obtained as a white solid in 58% yield from the product of Example 19, step (c) and 1-chloro-4-(chloromethyl)benzene.

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.41 (app d, 2H), 7.28 (app d, 2H), 4.39 (br s, 1H) overlapping with 4.34 (dd, 2H), 3.56-3.46 (m, 2H), 1.70-1.59 (m, 1H), 1.54-1.45 (m, 1H), 1.45-1.36 (m, 1H), 0.92 (d, 3H), 0.87 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 425 [M+H]<sup>+</sup>.

(b) 5-[(4-Chlorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-3-methylbutyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The title compound was obtained as a white solid in 25% yield (1:1 mixture of two unresolved diastereoisomers).

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.28 (app t, 2H), 7.12 (app d, 2H), 4.45 (br s, 1H) overlapping with 4.42 (dd, 2H from one diastereomer), 4.27 (dd, 2H from one diastereomer), 3.58-3.47 (m, 2H), 1.72-1.57 (m, 1H), 1.55-1.35 (m, 2H), 0.98-0.86 (m, 6H);

MS (ESI<sup>+</sup>) *m/z* 441 [M+H]<sup>+</sup>.

**Example 25**      5-[Benzyl-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl]-7-[[1*R*]-1-(hydroxymethyl)-2-methylpropyl]amino}[1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

The title compound was obtained from the product of Example 7, step (c) as a white solid in a 17% yield (1:1 mixture of two unresolved diastereoisomers) by following the procedure of Example 19, step (f).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 12.73 (br s, 1H), 7.63 (br s, 1H), 7.32-7.26 (m, 3H), 7.18-7.12 (m, 2H), 4.67-4.62 (m, 1H), 4.37 (dd, 2H from one diastereomer), 4.20 (d, 2H from one diastereomer), 4.12-4.02 (m, 1H), 3.60-3.45 (m, 2H), 1.95-1.85 (m, 1H), 0.93-0.83 (m, 6H);

MS (ESI<sup>+</sup>) *m/z* 393 [M+H]<sup>+</sup>.

### Pharmacological Screens

#### **Materials**

Recombinant human fractalkine (hCX<sub>3</sub>CL1) was purchased from PeproTech Inc., UK.

- 5 Recombinant [<sup>125</sup>I]-fractalkine (human), with a specific activity of 2200 Ci/mmol, was purchased from NEN<sup>®</sup> Life Science Products, Inc., UK. Fluo4-AM was purchased from Molecular Probes, US. All other chemicals were of analytical grade.

#### **Expression of human fractalkine receptor (hCX<sub>3</sub>CR1)**

- 10 The complete human CX<sub>3</sub>CR1 cDNA (GenBank accession number U20350) was extracted from human brain mRNA (Superscript, Life Technologies) and ligated into pCR-Blunt II TOPO vector (Invitrogen). The insert corresponding hCX<sub>3</sub>CR1 was isolated and further subcloned into pcDNA3.1zeo. Plasmid DNA was prepared using Plasmid Midi Kit (Qiagen). Using Superfect Transfection Reagent (Qiagen) according to the manufacture's
- 15 protocol the expression plasmid for hCX<sub>3</sub>CR1 was then introduced into human embryonic kidney suspension (HEKS) 293 cell line containing a vector for stable expression of a chimeric G-protein Gα<sub>q15</sub>. A stable clone was generated utilizing zeocin (500 µg/ml) and hygromycin (100 µg/ml) selection. For further applications the cells were maintained in Dulbecco's modified Eagle's medium/Ham's nutrient mix F12 (DMEM/F12) containing
- 20 pyridoxine and supplemented with 10% (v/v) fetal bovine serum, 2mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, 250 µg/ml zeocin and 100 µg/ml hygromycin.

#### **Ligand Binding Assay**

- 25 For the competition binding assay cells were harvested in buffer containing 10 mM Tris-HCl, pH 7.4, 5 mM ethylenediaminetetra-acetic acid (EDTA) and 0.1 mg/ml bacitracin (a protease inhibitor) and centrifuged at 300xg for 10 min. Cell pellets were then resuspended in harvesting buffer, pooled and homogenised using Dounce homogeniser. Cell membranes were centrifuged at 48000xg for 10 min and then resuspended in harvesting buffer using
- 30 Ultra-Turrax T8 (IKA Labortechnik, Germany). Protein concentration was determined in microtiter plates as described by Harrington (1990, Anal. Biochem. 186, 285 – 287). Membrane aliquotes were stored at -70 °C. Receptor expression was confirmed with [<sup>125</sup>I]-

fractalkine binding using whole cells. Competition binding assays were performed in 2ml 96-deep-well plates (Beckman, Germany) in a total volume of 1000  $\mu$ l/well. Each well contained 10 pM [ $^{125}$ I]-fractalkine and membrane equivalent to receptor concentration of 1 pM in assay buffer [50 mM Hepes-KOH, pH 7.4, 10 mM  $MgCl_2$ , 1 mM EDTA, 0,1 % (w/v) gelatin]. Test compounds were pre-dissolved in DMSO and added to reach a final concentration of 1 % (v/v) DMSO. The assay was initiated with the addition of membranes and incubated at 25°C for 24 h. Assay plates were filtrated with a Tomtec cell harvester (Tomtec, US) using ice-cold wash buffer (10mM Hepes-KOH pH 7.4, 500mM NaCl) and harvested onto printed filtermat B, GF/B (PerkinElmer LifeScience,US) presoaked in 0.3% polyetyhlenimine. MeltiLex solid scintillator (PerkinElmer LifeSciences,US) were melted onto filters and radioactivity was measured in a Wallac1205 Betaplate counter (PerkinElmer LifeScience, US).

### Solubility Assay

#### **Method Description**

100  $\mu$ M Solutions in duplicate, prepared by dilution from a 10 mM DMSO stock solution of the test compound, were incubated in 0.1M phosphate buffer, pH 7.4, in a 96-well plate (PP plate, 350  $\mu$ l U-shaped wells, COSTAR) on a plate bed shaker (IKA<sup>®</sup>-Schüttler MTS-4, IKA Labortechnik) at 300 rpm and room temperature (20-22 °C) for 24 hours.

The solutions were transferred to a MultiScreen<sup>™</sup>-R4 96-well filtration plate (LCR membrane, 0.4  $\mu$ m hydrophilic PTFE, non-sterile glass-filled PP plate, 350  $\mu$ l wells, Millipore) and filtered under vacuum to a 96-well collection plate (PP plate, 350  $\mu$ l U-shaped wells, COSTAR), called the analyte plate, using Millipore Vacuum Manifold equipment. The analyte plate was covered by heat-sealing with an aluminium foil coated with a PP seal layer (AB-0813, pierceable sealing foil strong, ABgene).

LC-UV-MS analysis was performed using a generic LC method.

Single point quantification was performed against two 100  $\mu$ M standards of the test compound dissolved in DMSO at the wavelength showing maximum UV absorbance as





extracted from the DAD-trace (210 - 400 nm). The upper limit of the screen method is 100  $\mu$ M with a LOQ of 0.1  $\mu$ M.

## Results

5 When tested in the ligand binding assay, the compounds of Examples 1 to 25 gave  $K_i$  values of less than 10  $\mu$ M, indicating that they are expected to show useful therapeutic activity. Representative ligand binding and solubility data are shown in the following Table in which four Examples from the present application are compared with the corresponding sulphide derivatives (X = S) from within the generic scope of

10 WO 01/25242:


10 WO 01/25242:

| Compound  |                        | Solubility<br>( $\mu$ M) | CX <sub>3</sub> CR1 Receptor<br>K <sub>i</sub> (nM) |
|---|------------------------|--------------------------|---|
|    | X = O<br>Example 1     | 29                       | 44.6  |
|   | X = S                  | 1.3                      | 50.0  |
|   | X = O<br>Example 2     | 78.5                     | 53.1  |
|   | X = S                  | 3.5                      | 45.0  |
|  | X = S(O)<br>Example 21 | > 100                    | 38.0  |
|   | X = S                  | 2.1                      | 10.0  |
|  | X = S(O)<br>Example 25 | > 100                    | 286.7   |
|   | X = S                  | 8.5                      | 179.1   |



Claims

1. A compound of formula (I)



(I)

wherein:

$R^1$  and  $R^2$  independently represent H, C1 to 8 alkyl, C2 to 8 alkenyl, C2 to 8 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; the latter four groups being optionally further substituted by one or more groups selected independently from OH, C1 to 6 alkoxy,  $CH_2OR^4$ ,  $NR^5R^6$ ,  $CO_2R^7$  and  $CONR^8R^9$ ;

$R^3$  represents C1 to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or alkynyl chain optionally including a O,  $NR^{10}$  or S atom in the chain; said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by phenyl or a 5 or 6 membered heteroaromatic ring containing 1 to 3 heteroatoms selected independently from O, S and N; said phenyl or heteroaromatic ring being optionally further substituted by one or more groups selected independently from halogen, C1 to 4 alkyl, OH, C1 to 4 alkoxy, CN,  $CO_2R^{11}$ ,  $NR^{12}R^{13}$ ,  $CONR^{14}R^{15}$ ,  $SO_2R^{16}$ ,  $NR^{17}SO_2R^{18}$  and  $SO_2NR^{19}R^{20}$ ;

X represents O or S(O);

$R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}$  and  $R^{20}$  independently represent H or C1 to 6 alkyl;

and pharmaceutically acceptable salts thereof.

5

2. A compound according to Claim 1 wherein  $R^1$  represents H or  $CH_3$ .

3. A compound according to Claim 1 or Claim 2 wherein  $R^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $CH_2OR^4$ .

10

4. A compound according to any one of Claims 1 to 3 wherein  $R^3$  represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

15

5. A compound of formula (I), according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use as a medicament.

6. A pharmaceutical formulation comprising a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.

20

7. A method of treating, or reducing the risk of, a human disease or condition in which antagonism of the  $CX_3CR1$  receptor is beneficial which comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof.

25


8. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which antagonism of the  $CX_3CR1$  receptor is beneficial.

30

9. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis or pain.

10. A process for the preparation of a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the process comprises:


- (a) when X in formula (I) represents O, reaction of a compound of formula (II)



(II)

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1;

with a compound of formula (III)




(III)

wherein R<sup>3</sup> is as defined in Claim 1 and is independent of the R<sup>3</sup> group in formula (II); or

- (b) when X in formula (I) represents S(O), oxidation of a compound of formula (IV)

43



(IV)


wherein  $R^1$ ,  $R^2$  and  $R^3$  are as defined in Claim 1; with one equivalent of an oxidising agent;

- 5 and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100

**Abstract**

There are disclosed novel compounds of formula (I)



(I)

5

wherein  $R^1$ ,  $R^2$ ,  $R^3$  and X are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX<sub>3</sub>CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis and pain.

10

7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148